Bio/Pharma Industry Works Overtime to Find COVID-19 Therapies

October 16, 2020
Feliza Mirasol

Feliza Mirasol is science editor at BioPharm International.

BioPharm International, BioPharm International-10-15-2020, Volume 2020 eBook, Issue 3
Page Number: 3–8

Bio/Pharma companies are galvanized to develop COVID-19 therapies under FDA’s acceleration program.

As part of the bio/pharmaceutical industry’s global response efforts for COVID-19, companies are also racing to develop therapies to treat COVID-19 in parallel with vaccine development efforts. As of Sept. 25, 2020, more than 590 drug development programs are in planning stages, and FDA has reviewed more than 310 trials, as of the end of August 2020, of potential COVID-19 therapies. The agency also published industry guidance in September 2020 around assessing symptoms in individuals undergoing clinical trials for COVID-19 therapies.

Read this article in BioPharm International’s Regulatory Sourcebook October 2020 eBook.

Article Details

BioPharm International
eBook: Regulatory Sourcebook, October 2020
October 2020
Pages: 3–8

Citation

When referring to this article, please cite it as F. Mirasol, “Bio/Pharma Industry Works Overtime to Find COVID-19 Therapies," BioPharm International Regulatory Sourcebook eBook (October 2020).